Source: International Congress 2014 – ILDs 4
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. J. Kohlhaeufl, H. Ingerl, M. Bachnik (Gerlingen-Stuttgart, Germany). Pirfenidone in idiopathic pulmonary fibrosis - description of a German cohort. Eur Respir J 2014; 44: Suppl. 58, 3749

Member's Comments

No comment yet.

Related content which might interest you: Predictors of efficacy of pirfenidone in idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 4 Year: 2014 Safety and efficacy of pirfenidone in severe idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 3 Year: 2014 IPFdatabase – A new tool for a correct application of idiopathic pulmonary fibrosis guidelines Source: International Congress 2014 – ILDs 2 Year: 2014 Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 3 Year: 2014 Assessment of telomere length in the combined pulmonary fibrosis and emphysema syndrome Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations Year: 2014 Long-term survival analysis: Pirfenidone compared to standard care for the treatment of patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Platelet activation indices in patients with Idiopathic Pulmonary Fibrosis Source: International Congress 2014 – ILDs 5 Year: 2014 Pirfenidone therapy for patients with progressive idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 3 Year: 2014 Reduction in disease progression with nintedanib in the INPULSIS™ trials Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Idiopathic pulmonary fibrosis is associated with a preferential alteration of kCO rather than of DLCO Source: International Congress 2014 – ILDs 6 Year: 2014 Intraindividual response to treatment with pirfenidone in two independent European IPF cohorts Source: International Congress 2014 – ILDs 2 Year: 2014 Pulmonary distribution and localization of pirfenidone in animal models of IPF by MS/MS Source: International Congress 2014 – ILDs 4 Year: 2014 Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Acute exacerbation of idiopathic pulmonary fibrosis: Analysis in a post-marketing surveillance of pirfenidone Source: International Congress 2014 – Clinical trials in IPF Year: 2014 The effect of pirfenidone with patients with idiopathic pulmonary fibrosis in one university hospital Source: International Congress 2014 – ILDs 4 Year: 2014 6MWT performance by means of Spiropalm in patients affected by fibrotic idiopathic interstitial pneumonias: Preliminary observations Source: International Congress 2014 – ILDs 6 Year: 2014 Transient elastography detection of early liver fibrosis in idiopathic pulmonary fibrosis patients Source: International Congress 2014 – ILDs 2 Year: 2014 Diffuse dendriform pulmonary ossification in a usual interstitial pneumonia-like distribution: A distinct entity or a variant of idiopathic pulmonary fibrosis? Source: International Congress 2014 – ILDs 1 Year: 2014 LATE-BREAKING ABSTRACT: Efficacy of Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF): an Italian real life study Source: International Congress 2014 – IPF and surroundings Year: 2014 Proportion of idiopathic pulmonary fibrosis among interstitial lung disease in a tertiary care center and its response to treatment Source: International Congress 2014 – ILDs 5 Year: 2014